ArticleFrontiers in artificial intelligence2026
Endophytic actinomycetes as a reservoir of novel chemotherapeutic leads against multidrug-resistant cancer.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance (MDR) has emerged as a major barrier to effective cancer control, undermining the efficacy of chemotherapy, targeted agents and, increasingly, immunotherapies. This review synthesizes current knowledge on the molecular and cellular bases of MDR in cancer, including ABC transporter-mediated drug efflux, enhanced DNA damage responses, survival-signaling rewiring, tumor-microenvironmental protection and cancer stem cell-driven plasticity. Particular emphasis is placed on endophytic actinomycetes and their metabolites as an underexploited reservoir of MDR modulating chemotypes with potent cytotoxic, resistance-reversal and microenvironment-modulating activities. By integrating recent mechanistic and pharmacological data, the review first delineates the crisis of drug-resistant cancer, then catalogs actinomycete-derived metabolites with documented efficacy against resistant cell lines, including those that inhibit efflux pumps, restore pro-apoptotic signaling or interfere with angiogenesis, epithelial-mesenchymal transition and stemness traits. Finally, translational challenges, such as suboptimal pharmacokinetics, off-target toxicity, herb-drug interactions and the paucity of biomarker-driven clinical trials, are critically examined alongside emerging strategies involving semi-synthetic optimization, nanocarrier delivery and rational combination regimens. A forward-looking discovery pipeline is proposed that couple's genome mining of endophytic actinomycetes with systematic MDR-mechanism profiling and medicinal chemistry, aiming to prioritize the most promising metabolites for preclinical and clinical development as next-generation MDR-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.